Zanaflex Capsule
Product Images NDC 83107-001

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 83107-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Legacy Pharma Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Tizanidine Hydrochloride Caps 2mg Bottle Label)

Zanaflex Capsules 2 mg label showing tizanidine hydrochloride as the active ingredient. The package contains 150 capsules. Manufactured for Legacy Pharma USA, Inc., with storage and safety information, barcode, and lot details visible. The label is primarily purple with distinct branding and dosage information.*

FDA Label Image

Principal Display Panel (Tizanidine Hydrochloride Caps 4mg Bottle Label)

Label for Zanaflex Capsules 4 mg (tizanidine hydrochloride) showing a count of 150 capsules. The label includes storage instructions, caution to keep out of reach of children, and states it is manufactured for Legacy Pharma USA, Inc. The label features a barcode, NDC 83107-002-15, and notes the product is made in the Czech Republic.*

FDA Label Image

Principal Display Panel (Tizanidine Hydrochloride Caps 6mg Bottle Label)

Label for Zanaflex capsules 6 mg (tizanidine hydrochloride) by Legacy Pharma USA, Inc. The label indicates a package size of 150 capsules, includes storage instructions, dosage reference, child-resistant closure warning, and manufacturer details. The label also displays a barcode and product lot and expiration fields.*

FDA Label Image

Figure 1 (Tizanidine Hydrochloride Graph 1)

A line graph showing plasma tizanidine concentration (ng/mL) over time (hours) after dosing with 2 x 4 mg tizanidine tablets or capsules, with and without food. Four distinct lines represent the different conditions: tablets with food, tablets without food, capsules with food, and capsules without food, highlighting the concentration changes up to 24 hours post-dose.*

FDA Label Image

Figure 2 (Tizanidine Hydrochloride Graph 2)

A line graph showing the improvement in Ashworth Score over time (hours post-dose) for 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph includes error bars for variability, illustrating greater improvement with both tizanidine doses compared to placebo, peaking around 2-3 hours post-dose before decreasing.*

FDA Label Image

Figure 3 (Tizanidine Hydrochloride Graph 3)

This line graph depicts improvement in Ashworth Score over time, comparing tizanidine (mean dose 28.8 mg) and placebo groups at three time points: End of Titration (Study Week 3), End of Maintenance (Week 24), and Endpoint (Last Observation). Data points include mean values with error bars.*

FDA Label Image

Structural Formula (Tizanidine Hydrochloride Structure)

Chemical structure of tizanidine hydrochloride, the active ingredient in Zanaflex capsules. The diagram shows the molecular arrangement of atoms including chlorine, nitrogen, sulfur, and hydrogen atoms forming the compound's distinctive rings.*

FDA Label Image

Principal Display Panel (Tizanidine Hydrochloride Tabs 4mg Bottle Label)

Label for Zanaflex 4 mg capsules by Legacy Pharma USA, Inc. The label states each tablet contains 4 mg tizanidine hydrochloride with a total of 150 tablets in the package. It includes storage instructions and a barcode, noting that the product is prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.